Purposecalgbswog 80405 was a randomized phase iii trial that found no statistically significant difference in overall survival os in. Calgb swog 80405 was a randomized phase iii trial of cetuximab or bevacizumab with folfiri or mfolfox6 for patients with kras wildtype untreated metastatic adenocarcinoma of the. A pediatric regimen for older adolescents and young adults. Calgb 80405 pdf asco, itt, kraswt primary os results. For those who are not ctsu members this website provides a listing of active protocols that the ctsu supports along with links to resources for additional information on ncifunded clinical trials. Calgb 80405 what this study is about a cancer study that compared different chemotherapy drug treatments for adults with colon or rectal cancer that has returned or spread throughout the body.
Both trials assessed the combination of either cetuximab or bevacizumab with. Barcelona, spainthe lead author of the calgb 80405 metastatic colorectal cancer trial was called to task here at the esmo world congress on gastrointestinal cancer for important data still to come, more than a year after overall survival and progression free survival data were presented at the asco 2014 annual meeting abstract lba 3, ot 71014 issue. Impact of consensus molecular subtype on survival in. Acute leukemia group b, algb is a cancer research cooperative group in the united states calgb research is focused on seven major disease areas. Three studies, the phase iii fire3 aio krk0306, the phase ii peak, and the recently presented phase iii calgb swog 80405 trial, have addressed this issue faceon, directly comparing the addition of bevacizumab versus cetuximab or panitumumab to folfoxfolfiri in terms of efficacy outcomes. Results from the calgb swog 80405 and fire3 aio krk0306 studies in all ras wild type population.
Researchers at the usc norris comprehensive cancer center found that identifying a metastatic colorectal cancer patients consensus molecular subtype cms could help oncologists determine the. Calgb swog 80405 is a phase iii trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as firstline treatment of advanced crc. Impact of consensus molecular subtyping cms on overall survival os and progression free survival pfs in patients pts with metastatic colorectal cancer mcrc. Mutational analysis of patients with colorectal cancer in calgb. Venook, md, discusses findings from the phase iii calgb swog 80405 trial that compared frontline therapy with bevacizumab or. Effect of firstline chemotherapy combined with cetuximab or. There was no difference in the progression free survival.
Predictive modeling in colorectal cancer annals of oncology. Os was defined as the time from randomization until death from any cause. The advances made in the therapeutic management of colorectal cancer crc over recent years with the addition of therapies targeting angiogenesis or cell proliferation have positioned bevacizumab, cetuximab, and panitumumab as accepted firstline treatments when combined with folfox or folfiri for ras wildtype wt metastatic crc. Calgb 80405 pharmacy contact tbn calgb 80405 nursing contact tbn this study is supported by the nci cancer trials support unit ctsu. Bayesian machine learning on calgbswog 80405 alliance.
The calgb swog 80405 trial n 17 is the largest headtohead trial with 2334 patients randomized. Patients without reported death were censored at their last known followup. Results from the calgbswog 80405 and fire3 aio krk0306. The alliance has been awarded a grant by the national cancer institute nci as a member of the nci national clinical trials network nctn. Analysis of all ras wt subgroup on calgb swog 80405 alliance. Folfiri or mfolfox6, combined with bv or cet, are 1 stline treatments for mcrc. Calgb swog 80405 was a randomized phase iii trial of cetuximab or bevacizumab with folfiri or mfolfox6 for patients with kras wildtype untreated metastatic adenocarcinoma of the colon or rectum. Causal modeling of calgb 80405 alliance identifies network drivers of metastatic colorectal cancer mcrc. Plasma 25hydroxyvitamin d levels and survival in patients. In an additional analysis, sidedness remained an independent prognostic factor. Pdf diabetes and clinical outcome in patients with metastatic.
There were 94 pts free of disease following surgery, median fu 40 mos range 8. Asco 2017 updates in colorectal and gastric cancers. Calgb failed to meet its primary endpoint of os cetuximab is not superior to avastin in 1l kraswt. Impact of primary tumor location on overall survival and. Secondary endpoints were progression free survival pfs and treatmentrelated adverse events. Institutions not aligned with the alliance will participate through the ctsu mechanism as outlined below and detailed in the ctsu logistical appendix. Overallsurvival progression free survival overall cetuximab bevacizumab overall cetuximab bevacizumab cms1 immune. Patients were treated with folfox or folfiri by the investigators discretion in. In the calgbswog 80405 trial here referred to as the. Publications home of jama and the specialty journals of. This analysis provides a new framework that connects alternative metrics of response to overall survival.
Costeffectiveness analysis of ras screening for treatment of metastatic colorectal cancer based on the calgb 80405 trial. Causal modeling of calgb 80405 alliance identifies network drivers of metastatic. However, there was higher response acheived in the cetuximab arm in the expanded ras population, 68. Pfs in patients pts with metastatic colorectal cancer mcrc. This site uses tracking technologies through the use of permanent cookies and web beaconspixel tags.
Current analyses multivariate analysis of prognostic utility of tumor sidedness independent of other molecular features 1 evaluated in subset of pts with left rightsided tumors no transverse and available molecular data. Berry first line treatment mcrc wcgccc saskatoon sept 2014. Cetuximab andor bevacizumab combined with combination. Patients were enrolled at 508 community and academic centers throughout the national clinical trials network. Calgb 80405 trial results in metastatic colorectal cancer.
Progressionfree survival and overall survival estimates by diabetes status. A randomized phase ii trial of pet scandirected combined modality therapy for esophageal cancer. Analysis of the ras wt population of calgbswog 80405 suggested. Calgb 80405is a recentlycompleted phase iii clinical trial of folfox. Burkitt lymphoma part 1 of 3 the selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. However, the influence of vitamin d status on disease progression and patient survival remains largely unknown for patients with advanced or metastatic crc. The primary endpoint of calgb swog 80405 alliance and this companion study was overall survival os. Hypothesis free machine learning approaches to this study dataset can provide valuable insights into mcrc prognosis and management of mcrc. Secondary endpoints were progressionfree survival pfs and treatmentrelated adverse events. Diabetes and clinical outcome in patients with metastatic. Previous studies have suggested that higher circulating 25hydroxyvitamin d 25ohd levels are associated with decreased colorectal cancer crc risk and improved survival. Impact of primary tumor location on overall survival and progression free survival in patients with metastatic colorectal cancer. Firstline treatment of metastatic colorectal cancer.
The alliance for clinical trials in oncology seeks to reduce the impact of cancer by uniting a broad community of scientists and clinicians who are committed to the prevention and treatment of cancer. Pts with ras wt codons 12 and mcrc and performance status 01 received folfiri or mfolfox6 mdpt choice at enrollment and randomized to either cet 400 mgm 2 x 1, then 250 mgm 2 qw or bv 5 mgkg q2w. To evaluate response, progression free survival pfs, time to treatment failure ttf, and duration of response dr among patients with unresectable advanced metastatic colon cancer treated with bevacizumab or cetuximab in addition to chemotherapy with folfiri or folfox. Thai n, wei lj, alas v, khalil i, berhanu p, dalal mr, sung j. A phase iii trial of irinotecan 5fu leucovorin or oxaliplatin 5fu. The primary exposure was physician documented diabetes at the time of enrollment. Calgb swog 80405 showed no difference in os or pfs between the addition of bevacizumab bv or cetuximab cet to chemotherapy with folfox or folfirii activating mutations at other codons within kras or nras have been associated with resistance to egfr inhibitors 2 current exploratory analysis investigated treatment effects in. For example, posthoc analyses of the calgbswog 80405 phase. Colorectal cancer is the second leading cause of cancer death in the u. In conclusion, proper interpretation of the calgb swog 80405 and fire3 results requires an indepth examination of the complex interplay, not only between the targeted biological agents and chemotherapeutic drugs, but also between therapies and the tumour biology and microenvironment, for each line of treatment. Researchers conducted the calgb 80405 study, a randomized phase 3 trial that demonstrated no differences in overall survival os or progression free survival pfs in patients with metastatic colorectal cancer mcrc treated with bevacizumab bv or cetuximab cet as first line therapy.
Use of a pediatric regimen for ayas with all up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. Causal modeling of calgb 80405 alliance identifies. Secondary objectives included progressionfree survival and overall response rate. The primary endpoint of calgbswog 80405 alliance and this companion study was overall survival os. This congress is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with. Progressionfree survival was similar between treatments. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and. Tumor location findings shed light on calgbswog 80405. The landmark calgb swog 80405 study found that overall survival was 14 months better for patients with leftsided tumors, vs rightsided ones.
1563 1192 1417 681 566 1573 1233 992 3 1579 832 1085 1178 1142 63 1187 1343 325 581 7 322 2 639 1153 1574 1086 1190 382 357 1365 554 152 1514 1260 230 866 974 588 698 1255